AMARIN CORP PLC\UK Cost of Goods Sold (Deprecated 2018-01-31)
AMARIN CORP PLC\UK (AMRN) reported Cost of Goods Sold (Deprecated 2018-01-31) of $10.65 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-02.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-05-02
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $10.65M, a 29.89% increase year-over-year.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $13.43M, a 32.27% increase year-over-year.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $11.92M, a 41.06% increase year-over-year.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $11.40M, a 28.66% increase year-over-year.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $44.95M, a 30.82% increase from fiscal 2016.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $34.36M, a 23.28% increase from fiscal 2015.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $27.88M, a 36.08% increase from fiscal 2014.
- AMARIN CORP PLC\UK cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $20.48M, a 71.97% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $10.65M 10-Q · filed 2018-05-02 | $24.08M derived: sum of 2 quarters · filed 2018-05-02 | $36.00M derived: sum of 3 quarters · filed 2018-05-02 | $47.40M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-12-31 | $13.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $25.35M derived: sum of 2 quarters · filed 2018-02-27 | $36.75M derived: sum of 3 quarters · filed 2018-02-27 | $44.95M 10-K · filed 2018-02-27 |
| 2017-09-30 | $11.92M 10-Q · filed 2017-11-01 | $23.32M derived: sum of 2 quarters · filed 2017-11-01 | $31.52M 10-Q · filed 2017-11-01 | $41.67M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-06-30 | $11.40M 10-Q · filed 2017-08-02 | $19.60M 10-Q · filed 2017-08-02 | $29.75M derived: sum of 3 quarters · filed 2018-05-02 | $38.20M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | $8.20M 10-Q · filed 2018-05-02 | $18.35M derived: sum of 2 quarters · filed 2018-05-02 | $26.80M derived: sum of 3 quarters · filed 2018-05-02 | $35.66M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $10.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $18.61M derived: sum of 2 quarters · filed 2018-02-27 | $27.47M derived: sum of 3 quarters · filed 2018-02-27 | $34.36M 10-K · filed 2018-02-27 |
| 2016-09-30 | $8.45M 10-Q · filed 2017-11-01 | $17.31M derived: sum of 2 quarters · filed 2017-11-01 | $24.21M 10-Q · filed 2017-11-01 | $32.60M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $8.86M 10-Q · filed 2017-08-02 | $15.76M 10-Q · filed 2017-08-02 | $24.15M derived: sum of 3 quarters · filed 2018-02-27 | $31.62M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $6.90M 10-Q · filed 2017-05-03 | $15.29M derived: sum of 2 quarters · filed 2018-02-27 | $22.76M derived: sum of 3 quarters · filed 2018-02-27 | $29.14M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $15.87M derived: sum of 2 quarters · filed 2018-02-27 | $22.25M derived: sum of 3 quarters · filed 2018-02-27 | $27.88M 10-K · filed 2018-02-27 |
| 2015-09-30 | $7.48M 10-Q · filed 2016-11-03 | $13.86M derived: sum of 2 quarters · filed 2016-11-03 | $19.49M 10-Q · filed 2016-11-03 | $25.33M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $6.38M 10-Q · filed 2016-08-04 | $12.01M 10-Q · filed 2016-08-04 | $17.86M derived: sum of 3 quarters · filed 2017-03-01 | $23.22M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $5.63M 10-Q · filed 2016-05-05 | $11.47M derived: sum of 2 quarters · filed 2017-03-01 | $16.84M derived: sum of 3 quarters · filed 2017-03-01 | $21.87M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $11.21M derived: sum of 2 quarters · filed 2017-03-01 | $16.24M derived: sum of 3 quarters · filed 2017-03-01 | $20.48M 10-K · filed 2017-03-01 |
| 2014-09-30 | $5.37M 10-Q · filed 2015-11-04 | $10.39M derived: sum of 2 quarters · filed 2015-11-04 | $14.64M 10-Q · filed 2015-11-04 | $18.74M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $5.03M 10-Q · filed 2015-08-06 | $9.27M 10-Q · filed 2015-08-06 | $13.37M derived: sum of 3 quarters · filed 2016-02-25 | $17.05M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $4.25M 10-Q · filed 2015-05-08 | $8.35M derived: sum of 2 quarters · filed 2016-02-25 | $12.03M derived: sum of 3 quarters · filed 2016-02-25 | $14.87M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $7.78M derived: sum of 2 quarters · filed 2016-02-25 | $10.63M derived: sum of 3 quarters · filed 2016-02-25 | $11.91M 10-K · filed 2016-02-25 |
| 2013-09-30 | $3.68M 10-Q · filed 2014-11-06 | $6.53M derived: sum of 2 quarters · filed 2014-11-06 | $7.81M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $2.84M 10-Q · filed 2014-08-07 | $4.13M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $1.29M 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |